Kezar Life Sciences, Inc.

This study tested an experimental drug called KZR-616 in 69 people with lupus, some of whom also had kidney inflammation (lupus nephritis). The goal was to see if the drug is safe and can reduce kidney damage. Participants received weekly injections for 13 or 24 weeks. The result…

This study looked at the long-term safety and effectiveness of an experimental drug called KZR-616 in people with active polymyositis or dermatomyositis, two rare diseases that cause muscle inflammation and weakness. The 18 participants had already completed a previous study and …

This study tested an experimental drug called KZR-616 in 25 adults with active polymyositis or dermatomyositis, two rare diseases that cause muscle inflammation and weakness. Participants received weekly injections of the drug or a placebo for 16 weeks, then switched to the other…

This study tested a new drug called zetomipzomib in 24 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. Participants received either the drug or a placebo alongside their usual treatment for 24 weeks, with an option to continue the drug for…